Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Either bevacizumab or EGFR antibodies - 100004

Spotlight
Video

Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Either bevacizumab or EGFR antibodies

imedex has 1231 videos Subscribe Here

Loading........
Description: In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that either bevacizumab or EGFR antibodies are the preferred targeted therapy for RAS/BRAF wild-type left sided colon cancers.

Earn CME Credit for a related activity: http://elc.imedex.com/ELC/S...

© 2017 Imedex, LLC.
Shared By : imedex
Posted on : 10/13/17
Added : 1 year ago